Demographics (1)
- SEX - Gender of participant (phv00308243.v1.p1)
Disease Events (6)
- AFFECTION_STATUS - Case control status of the subject for neoadjuvant androgen deprivation (phv00308235.v1.p1)
- CELLULARITY - Percent of tissue with residual tumor (phv00308247.v1.p1)
- GLEASON - Gleason score at diagnosis (phv00308242.v1.p1)
- IS_TUMOR - Tumor status (phv00308252.v1.p1)
- RCB - Residual cancer burden (phv00308248.v1.p1)
- YPT - Pathologic T-stage after treatment (phv00308246.v1.p1)
Reproductive Health (1)
- PSA - Baseline PSA at time of diagnosis (phv00308244.v1.p1)
Other (15)
- ANALYTE_TYPE - Analyte Type (phv00308251.v1.p1)
- BODY_SITE - Body site where sample was collected (phv00308250.v1.p1)
- CONSENT - Consent group as determined by DAC (phv00308234.v1.p1)
- CORESPOS - Number of positive biopsy cores (phv00308245.v1.p1)
- FOCUS - Region of tissue where sample was acquired (phv00308253.v1.p1)
- GEO_ACCESSION - GEO accession ID (phv00309970.v1.p1)
- GROUP - Treatment arm (phv00308241.v1.p1)
- SAMPLE_ID - De-identified Sample ID (phv00308249.v1.p1)
- SAMPLE_ID - Sample ID (phv00308237.v1.p1)
- SAMPLE_ID - Sample ID (phv00309969.v1.p1)
- SAMPLE_USE - Sample Use (phv00308238.v1.p1)
- STUDY_ID - Patient ID used in publication (phv00308240.v1.p1)
- SUBJECT_ID - De-identified Subject ID (phv00308239.v1.p1)
- SUBJECT_ID - Subject ID (phv00308233.v1.p1)
- SUBJECT_ID - Subject ID (phv00308236.v1.p1)